First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients

Vikas Prasad, Friedemann Zengerling, Jochen P. Steinacker, Christian Bolenz, Meinrad Beer, Thomas Wiegel, Matthias Eiber, Neil Fleshner, Ambros J. Beer

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostatespecificmembrane antigen (PSMA) inmetastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients.

Original languageEnglish
Pages (from-to)975-979
Number of pages5
JournalJournal of Nuclear Medicine
Volume62
Issue number7
DOIs
StatePublished - 1 Jul 2021

Keywords

  • 177Lu
  • PSMA
  • olaparib
  • pembrolizumab

Fingerprint

Dive into the research topics of 'First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients'. Together they form a unique fingerprint.

Cite this